08/25/2026
The approval makes Imaavy the first treatment cleared for warm autoimmune hemolytic anemia, or wAIHA, and covers patients aged 12 and older who are currently or were previously treated with steroids.
The life-threatening disease causes the immune system to destroy red blood cells, leading to severe anemia, fatigue, blood clots and kidney failure.
The U.S. Food and Drug Administration has approved the expanded use of Johnson & Johnson's drug to treat a rare blood disorder, the company said on Monday.